Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats

Reuters

09/13

<a href="https://laohu8.com/S/ZTS">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats

Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency $(EMA)$ has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2567903319"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567903319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567903319?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-13 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567903319","market":"us","top_or_hot":-1,"title":"Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZTS\">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-13 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ZTS\">Zoetis Inc.</a> Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency <a href=\"https://laohu8.com/S/EMA\">$(EMA)$</a> has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0079474960.USD","symbol_name":"联博美国增长基金A","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL8xshHl:1","article_id":"2567903319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567903319","pubTimestamp":1757693355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products  of the European Medicines Agency  has issued a positive opinion recommending the granting of marketing authorization for Portela . This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0079474960.USD":"联博美国增长基金A","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","BK4007":"制药","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0058720904.USD":"联博国际健康护理基金A","LU0385154629.USD":"贝莱德营养科学基金A2","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU2308191902.HKD":"BNP PARIBAS ECOSYSTEM RESTORATION \"CLASSIC\" (HKD) ACC","ZTS":"Zoetis Inc.","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC"},"translate_title":"硕腾公司(Zoetis Inc.)获得欧洲药品管理局对Portela的积极评价®缓解猫的骨关节炎疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":0.9},"content_text":"Zoetis Inc. Receives Positive Opinion from European Medicines Agency for Portela® to Alleviate Osteoarthritis Pain in Cats\n    \n\n        Zoetis Inc. has announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency $(EMA)$ has issued a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab). This new monoclonal antibody therapy is designed to alleviate pain associated with osteoarthritis in cats. If approved, Portela will be the first long-acting anti-NGF monoclonal antibody therapy for cats, offering a solution that requires injections only once every three months. The European Commission is expected to make a decision during the fourth quarter of 2025, with commercial availability anticipated in the European Union in 2026. This development marks another milestone in Zoetis' commitment to advancing feline medicine and enhancing the quality of life for cats with osteoarthritis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250912419265) on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}